Memphasys Ltd (AU:MEM) — Market Cap & Net Worth
Market Cap & Net Worth: Memphasys Ltd (MEM)
Memphasys Ltd (AU:MEM) has a market capitalization of $13.11 Million (AU$18.52 Million) as of September 24, 2026. Listed on the AU stock exchange, this Australia-based company holds position #26465 globally and #1208 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Memphasys Ltd's stock price AU$0.01 by its total outstanding shares 3087233743 (3.09 Billion). Also see MEM total assets for a full breakdown of the balance sheet.
Memphasys Ltd Market Cap History: 2015 to 2026
Memphasys Ltd's market capitalization history from 2015 to 2026. Data shows change from $808.01 Million to $13.11 Million (-30.92% CAGR). Also see cash efficiency ratio of Memphasys Ltd for how efficiently the company converts equity into cash flow.
Memphasys Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Memphasys Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Memphasys Ltd share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
29.02x
Memphasys Ltd's market cap is 29.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $107.47 Million | $63.96K | -$2.17 Million | 1680.32x | N/A |
| 2021 | $203.15 Million | $211.48K | -$1.49 Million | 960.60x | N/A |
| 2022 | $30.58 Million | $27.15K | -$2.08 Million | 1126.48x | N/A |
| 2023 | $26.21 Million | $15.37K | -$3.40 Million | 1705.35x | N/A |
| 2024 | $17.48 Million | $60.00K | -$4.44 Million | 291.26x | N/A |
| 2025 | $15.29 Million | $526.92K | -$4.94 Million | 29.02x | N/A |
Competitor Companies of MEM by Market Capitalization
Companies near Memphasys Ltd in the global market cap rankings as of September 24, 2026. Review tangible net worth ratio of Memphasys Ltd to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Memphasys Ltd by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #122 globally with a market cap of $180.30 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #228 globally with a market cap of $109.30 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #237 globally with a market cap of $105.52 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #240 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #122 | Abbott Laboratories | NYSE:ABT | $180.30 Billion | $103.69 |
| #228 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $90.77 |
| #237 | Stryker Corporation | NYSE:SYK | $105.52 Billion | $275.09 |
| #240 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Memphasys Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Memphasys Ltd's market cap moved from $808.01 Million to $ 13.11 Million, with a yearly change of -30.92%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$13.11 Million | -14.29% |
| 2025 | AU$15.29 Million | -12.50% |
| 2024 | AU$17.48 Million | -33.33% |
| 2023 | AU$26.21 Million | -14.29% |
| 2022 | AU$30.58 Million | -84.95% |
| 2021 | AU$203.15 Million | -7.00% |
| 2020 | AU$218.44 Million | +100.00% |
| 2019 | AU$109.22 Million | +81.16% |
| 2018 | AU$60.29 Million | -6.44% |
| 2017 | AU$64.44 Million | -40.04% |
| 2016 | AU$107.47 Million | -86.70% |
| 2015 | AU$808.01 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 23rd, 2026 the market cap of Memphasys Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $13.11 Million USD |
| MoneyControl | $13.11 Million USD |
| MarketWatch | $13.11 Million USD |
| marketcap.company | $13.11 Million USD |
| Reuters | $13.11 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Memphasys Ltd
Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company offers Felix system, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, a rapid in vitro antioxidant assessment; and AI-Port… Read more